Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET
Company Participants
Matthew Calistri - Vice President of Investor Relations
Tony Coles - Chairperson & Chief Executive Officer
Ray Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Mark Bodenrader - Interim Chief Financial Officer
Conference Call Participants
Michael Yee - Jefferies
Matthew Harrison - Morgan Stanley
Paul Matteis - Stifel
Douglas Tsao - H.C. Wainwright
Omari Baruti - Goldman Sachs
Tiffany Sun - JPMorgan
Operator
Good morning. Welcome to the Cerevel Therapeutics Fourth Quarter and Full Year 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call maybe recorded.
I will now hand the call over to Matt Calistri, Vice President, Corporate Strategy and Investor Relations.
Matthew Calistri
Thank you. Good morning, everyone. We appreciate you joining us for our fourth quarter and full year 2021 earnings call. On today's call, you will be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer
During our call today, please refer to our press release from this morning, detailing our 2021 performance as well as our updated corporate presentation, both of which are available on our website.
I would like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding
- Read more current CERE analysis and news
- View all earnings call transcripts